Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Slavisa Ninkovic, Simon J. Harrison & Hang Quach. (2020) Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma. Expert Review of Hematology 13:11, pages 1201-1210.
Read now
Read now
Hailong Tang, Mimi Shu, Bo Dai, Li Xu, Baoxia Dong, Guangxun Gao & Xiequn Chen. (2018) DNA damage response-initiated cytokine secretion in bone marrow stromal cells promotes chemoresistance of myeloma cells. Leukemia & Lymphoma 59:9, pages 2220-2226.
Read now
Read now
Alex Vasuthasawat, Esther M. Yoo, Kham R. Trinh, Alan Lichtenstein, John M. Timmerman & Sherie L. Morrison. (2016) Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma. mAbs 8:7, pages 1386-1397.
Read now
Read now
Katherine M Dunlap, Mee Y Bartee & Eric Bartee. (2015) Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor–resistant multiple myeloma. Oncolytic Virotherapy 4, pages 1-11.
Read now
Read now
Michael D. Bright, Daniel N. Itzhak, Christopher P. Wardell, Gareth J. Morgan & Faith E. Davies. (2015) Cleavage of BLOC1S1 mRNA by IRE1 Is Sequence Specific, Temporally Separate from XBP1 Splicing, and Dispensable for Cell Viability under Acute Endoplasmic Reticulum Stress. Molecular and Cellular Biology 35:12, pages 2186-2202.
Read now
Read now
Huawen Li, Guoqiang Chang, Jian Wang, Lihong Wang, Weina Jin, Yani Lin, Yan Yan, Ruojun Wang, Wei Gao, Li Ma, Qinghua Li & Tianxiang Pang. (2014) Cariporide sensitizes leukemic cells to tumor necrosis factor related apoptosis-inducing ligand by up-regulation of death receptor 5 via endoplasmic reticulum stress–CCAAT/enhancer binding protein homologous protein dependent mechanism. Leukemia & Lymphoma 55:9, pages 2135-2140.
Read now
Read now
Rashid Z Khan & Ashraf Badros. (2012) Role of carfilzomib in the treatment of multiple myeloma. Expert Review of Hematology 5:4, pages 361-372.
Read now
Read now
Alexander Yemelyanov, Pankaj Bhalla, Ximing Yang, Andrey Ugolkov, Kenichi Iwadate, Apollon Karseladze & Irina Budunova. (2012) Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells. Cell Cycle 11:2, pages 395-406.
Read now
Read now
Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, Robert Schlossman, Dharminder Chauhan, Nikhil Munshi, Irene Ghobrial, Nicole Carreau, Kenneth C Anderson & Paul G Richardson. (2009) Bortezomib in the management of multiple myeloma. Cancer Management and Research 1, pages 107-117.
Read now
Read now
Articles from other publishers (41)
Yirong Chen, Yuchen Tao, Kexin Hu & Jiahui Lu. (2023) GRP78 inhibitor HA15 increases the effect of Bortezomib on eradicating multiple myeloma cells through triggering endoplasmic reticulum stress. Heliyon 9:9, pages e19806.
Crossref
Crossref
Xiaoying Lan, Min Hu, Liling Jiang, Jiamin Wang, Yi Meng, Xinmei Chen, Aochu Liu, Wa Ding, Haichuan Zhang, Huan Zhou, Bingyuan Liu, Guanjie Peng, Siyan Liao, Xin Chen, Jinbao Liu & Xianping Shi. (2023) Piperlongumine overcomes imatinib resistance by inducing proteasome inhibition in chronic myelogenous leukemia cells. Journal of Ethnopharmacology 301, pages 115815.
Crossref
Crossref
Mailee Huynh, Hae Yeun Chang, Dominique N. Lisiero, Irene M. Ong, Trinayan Kashyap, Natalie S. Callander & Shigeki Miyamoto. (2022) HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs. PLOS ONE 17:12, pages e0274704.
Crossref
Crossref
Dalia Quwaider, Luis A. Corchete, Marta Martín-Izquierdo, Jesús M. Hernández-Sánchez, Elizabeta A. Rojas, Ignacio J. Cardona-Benavides, Ramón García-Sanz, Ana B. Herrero & Norma C. Gutiérrez. (2022) RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation. Experimental Hematology & Oncology 11:1.
Crossref
Crossref
Jianhao Liu, Ruogang Zhao, Xiaowen Jiang, Zhaohuan Li & Bo Zhang. (2021) Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations. Biomolecules 12:1, pages 51.
Crossref
Crossref
Shansa Pranami E. Jayaweera, Sacheela Prasadi Wanigasinghe Kanakanamge, Dharshika Rajalingam & Gayathri N. Silva. (2021) Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma. Frontiers in Oncology 11.
Crossref
Crossref
Joske Ubels, Pieter Sonneveld, Martin H. van Vliet & Jeroen de Ridder. (2020) Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma. Clinical Cancer Research 26:22, pages 5952-5961.
Crossref
Crossref
Tina Bagratuni, Dimitrios Patseas, Nefeli Mavrianou-Koutsoukou, Christine Ivy Liacos, Aimilia D. Sklirou, Pantelis Rousakis, Maria Gavriatopoulou, Evangelos Terpos, Ourania E. Tsitsilonis, Ioannis P. Trougakos, Efstathios Kastritis & Meletios A. Dimopoulos. (2020) Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. Cancers 12:10, pages 2864.
Crossref
Crossref
Xuan Wu, Jiliang Xia, Jingyu Zhang, Yinghong Zhu, Yangbowen Wu, Jiaojiao Guo, Shilian Chen, Qian Lei, Bin Meng, Chunmei Kuang, Xiangling Feng, Yanjuan He, Yi Shen, Xin Li, Lugui Qiu, Guancheng Li & Wen Zhou. (2020) Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma. British Journal of Haematology 190:1, pages 52-66.
Crossref
Crossref
Daniela Correia da Silva, Patrícia Valentão, Paula B. Andrade & David M. Pereira. (2020) Endoplasmic reticulum stress signaling in cancer and neurodegenerative disorders: Tools and strategies to understand its complexity. Pharmacological Research 155, pages 104702.
Crossref
Crossref
Li Xu, Juan Feng, Hailong Tang, Ying Dong, Mimi Shu & Xiequn Chen. (2020) Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib. Cell Death & Disease 11:4.
Crossref
Crossref
Tina Bagratuni, Aimilia D. Sklirou, Efstathios Kastritis, Christine Ivy Liacos, Christina Spilioti, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Maria Gavriatopoulou, Evangelos Terpos, Ioannis P. Trougakos & Meletios A. Dimopoulos. (2019) Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop. Scientific Reports 9:1.
Crossref
Crossref
Chao Jiang, Rui Xu, Xiao-Xing Li, Yu-Feng Zhou, Xiao-Yi Xu, Yang Yang, Hui-Yun Wang & X.F. Steven Zheng. (2018) Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma. Molecular Cancer Therapeutics 17:12, pages 2610-2621.
Crossref
Crossref
Weizheng Geng, Xin Guo, Lirong Zhang, Yiming Ma, Lei Wang, Zhen Liu, Hong Ji & Ying Xiong. (2018) Resveratrol inhibits proliferation, migration and invasion of multiple myeloma cells via NEAT1-mediated Wnt/β-catenin signaling pathway. Biomedicine & Pharmacotherapy 107, pages 484-494.
Crossref
Crossref
Liping Luo, Wanxiang Jiang, Hui Liu, Jicheng Bu, Ping Tang, Chongyangzi Du, Zhipeng Xu, Hairong Luo, Bilian Liu, Bo Xiao, Zhiguang Zhou & Feng Liu. (2018) De-silencing Grb10 contributes to acute ER stress-induced steatosis in mouse liver. Journal of Molecular Endocrinology 60:4, pages 285-297.
Crossref
Crossref
Mailee Huynh, Chorom Pak, Stephanie Markovina, Natalie S. Callander, Kenneth S. Chng, Shelly M. Wuerzberger-Davis, Debayan D. Bakshi, John A. Kink, Peiman Hematti, Chelsea Hope, Fotis Asimakopoulos, Lixin Rui & Shigeki Miyamoto. (2018) Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma. Journal of Biological Chemistry 293:7, pages 2452-2465.
Crossref
Crossref
Kevin Barley & Samir Parekh. 2018. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
45
71
.
Gergely Varga, Gábor Mikala, Katalin Piroska Kiss, Éva Kosóczki, Edit Szabó, Nóra Meggyesi, Katalin Balassa, Petra Kövy, Bálint Tegze, Gergely Szombath, Attila Tordai, Hajnalka Andrikovics, László Homolya & Tamás Masszi. (2017) Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 17:11, pages 734-742.
Crossref
Crossref
Xiaoxuan Xu, Junru Liu, Beihui Huang, Meilan Chen, Shiwen Yuan, Xiaozhe Li & Juan Li. (2016) Reduced Response of IRE1α/Xbp-1 Signaling Pathway to Bortezomib Contributes to Drug Resistance in Multiple Myeloma Cells. Tumori Journal 103:3, pages 261-267.
Crossref
Crossref
Yiwen Bu & J. Alan Diehl. (2016) PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development. Journal of Cellular Physiology 231:10, pages 2088-2096.
Crossref
Crossref
Michael W Graner. (2015) The unfolded protein response in glioblastomas: targetable or trouble?. Future Science OA 1:2.
Crossref
Crossref
Ping Zhou, Xun Ma, Lakshmanan Iyer, Chakra Chaulagain & Raymond L. Comenzo. (2014) One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress. Blood 123:22, pages 3440-3451.
Crossref
Crossref
Li Yin, Turner Kufe, David Avigan & Donald Kufe. (2014) Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. Blood 123:19, pages 2997-3006.
Crossref
Crossref
F Loreni, M Mancino & S Biffo. (2013) Translation factors and ribosomal proteins control tumor onset and progression: how?. Oncogene 33:17, pages 2145-2156.
Crossref
Crossref
Maximilian Wei-Lin Popp & Lynne E. Maquat. (2013) Organizing Principles of Mammalian Nonsense-Mediated mRNA Decay. Annual Review of Genetics 47:1, pages 139-165.
Crossref
Crossref
Michael W Graner. (2013) The unfolded protein response in glioblastomas: passing the stress test. CNS Oncology 2:6, pages 469-472.
Crossref
Crossref
Alessandra Romano, Concetta Conticello & Francesco Di Raimondo. (2013) Bortezomib for the treatment of previously untreated multiple myeloma. Immunotherapy 5:4, pages 327-352.
Crossref
Crossref
Utkarsh PainulyShaji Kumar. (2013) Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma. Clinical Medicine Insights: Oncology 7, pages CMO.S7764.
Crossref
Crossref
Susanne B. Breitkopf, Min YuanGerman A. Pihan & John M. Asara. (2012) Detection of a rare BCR–ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS). Proceedings of the National Academy of Sciences 109:40, pages 16190-16195.
Crossref
Crossref
Shiloh M Martin, Eric Churchill, Hayes McKnight, Christopher M Mahaffey, Yunpeng Ma, Robert T O'Donnell & Joseph M Tuscano. (2011) The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner. Journal of Hematology & Oncology 4:1.
Crossref
Crossref
Ana Mozos, Gaël Roué, Armando López-Guillermo, Pedro Jares, Elias Campo, Dolors Colomer & Antonio Martinez. (2011) The Expression of the Endoplasmic Reticulum Stress Sensor BiP/GRP78 Predicts Response to Chemotherapy and Determines the Efficacy of Proteasome Inhibitors in Diffuse Large B-Cell Lymphoma. The American Journal of Pathology 179:5, pages 2601-2610.
Crossref
Crossref
John D. ShaughnessyJrJrPingping Qu, Saad UsmaniChristoph J. HeuckQing ZhangYiming ZhouErming TianIchiro Hanamura, Frits van RheeElias AnaissieJoshua EpsteinBijay NairOwen StephensRyan WilliamsSarah WaheedYazan AlsayedJohn Crowley & Bart Barlogie. (2011) Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood 118:13, pages 3512-3524.
Crossref
Crossref
Courtney M. Shirley, Jianmeng Chen, Meir Shamay, Huili Li, Cynthia A. Zahnow, S. Diane Hayward & Richard F. Ambinder. (2011) Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood 117:23, pages 6297-6303.
Crossref
Crossref
Harmeet Malhi & Randal J. Kaufman. (2011) Endoplasmic reticulum stress in liver disease. Journal of Hepatology 54:4, pages 795-809.
Crossref
Crossref
Paul G. Richardson, Constantine S. Mitsiades, Jacob P. Laubach, Sagar Lonial, Asher A. Chanan-Khan & Kenneth C. Anderson. (2011) Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. British Journal of Haematology 152:4, pages 367-379.
Crossref
Crossref
G. Roue, P. Perez-Galan, A. Mozos, M. Lopez-Guerra, S. Xargay-Torrent, L. Rosich, I. Saborit-Villarroya, E. Normant, E. Campo & D. Colomer. (2010) The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 117:4, pages 1270-1279.
Crossref
Crossref
David J. Cox, Natalie Strudwick, Ahmed A. Ali, Adrienne W. Paton, James C. Paton & Martin Schröder. 2011. The Unfolded Protein Response and Cellular Stress, Part C. The Unfolded Protein Response and Cellular Stress, Part C
261
292
.
Sarah K. Brennan, Brooke Meade, Qiuju Wang, Akil A. Merchant, Jeanne Kowalski & William Matsui. (2010) Mantle cell lymphoma activation enhances bortezomib sensitivity. Blood 116:20, pages 4185-4191.
Crossref
Crossref
Jing Zhang & Albert C. Koong. 2010. Tumor Microenvironment. Tumor Microenvironment
291
310
.
Jason J Everly, R Carlin Walsh, Rita R Alloway & E Steve Woodle. (2009) Proteasome inhibition for antibody-mediated rejection. Current Opinion in Organ Transplantation 14:6, pages 662-666.
Crossref
Crossref
J J Shah & R Z Orlowski. (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23:11, pages 1964-1979.
Crossref
Crossref